消息稱諾威健康在私募市場收到具吸引力的提議
格隆匯9月14日丨諾威健康已於9月5日通過了港交所聆訊,但有消息稱,公司近日在私募市場收到了具吸引力的提議,這爲其區域和全球擴張以及持續的世界級技術投資資金來源提供了更多選擇。
諾威健康是亞太區最大的專注於生物技術的CRO(合約研究組織)公司,在亞太地區擁有廣泛的網絡。2020年,公司48.4%的收入來自亞太地區的客戶。
在亞太區具有明顯優勢的同時,通過一系列成功的併購,使得公司擁有多樣化的全球生物技術客戶羣。通過對CNS和Biosuntek的戰略收購以及與PPC集團的合併,諾威健康擴大了其地理存在和服務能力。另外,公司與美國和歐洲領先的CRO合作,包括Precision for Medicine、Catalyst臨牀研究、Ergmed和ProTrials Research,通過擴大客戶網絡來促進業務發展。
2018-2020年,公司收入年複合增長率爲32.2%;同期調整後EBITDA強勁增長,複合年增長率爲92.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.